• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Masimo Corporation

    9/25/24 4:01:23 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $MASI alert in real time by email
    SC 13D/A 1 tm2424680d1_sc13da.htm SC 13D/A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

                                

     

    SCHEDULE 13D

    (Rule 13d-101)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(a)

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 15)*

     

    Masimo Corporation

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    574795100

    (CUSIP Number)

     

    Quentin Koffey

    Politan Capital Management LP

    106 West 56th Street, 10th Floor

    New York, New York 10019

    646-690-2830

     

    With a copy to:

     

    Richard M. Brand

    Cadwalader, Wickersham & Taft LLP

    200 Liberty Street

    New York, NY 10281

    212-504-6000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    September 24, 2024

    (Date of Event Which Requires Filing of This Statement)

                                

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ¨

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

      

    CUSIP No. 574795100

      Page 2

     

    1

    NAME OF REPORTING PERSON

    Politan Capital Management LP

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) x  (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

     

    OO (See Item 3)

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

    ¨

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    Number of
    shares
    beneficially
    owned by
    each
    reporting
    person
    with
    7

    SOLE VOTING POWER

     

    0

    8

    SHARED VOTING POWER

     

    4,713,518

    9

    SOLE DISPOSITIVE POWER

     

    0

    10

    SHARED DISPOSITIVE POWER

     

    4,713,518

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,713,518

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    8.8%*

    14

    TYPE OF REPORTING PERSON

     

    IA

    * All percentage calculations set forth herein are based upon the aggregate of 53,470,864 shares of Common Stock outstanding as of August 12, 2024, as reported in the Issuer’s revised definitive proxy statement, filed with the Securities and Exchange Commission (the “SEC”) on August 22, 2024 (the “Issuer Revised Proxy Statement”).

     

     

     

     

    CUSIP No. 574795100   Page 3

     

    1

    NAME OF REPORTING PERSON

    Politan Capital Management GP LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) x  (b) ¨

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    OO (See Item 3)

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

    ¨

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    Number of
    shares
    beneficially
    owned by
    each
    reporting
    person
    with
    7

    SOLE VOTING POWER

     

    0

    8

    SHARED VOTING POWER

     

    4,713,518

    9

    SOLE DISPOSITIVE POWER

     

    0

    10

    SHARED DISPOSITIVE POWER

     

    4,713,518

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,713,518

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    8.8%*

    14

    TYPE OF REPORTING PERSON

     

    IA

    * All percentage calculations set forth herein are based upon the aggregate of 53,470,864 shares of Common Stock outstanding as of August 12, 2024, as reported in the Issuer Revised Proxy Statement. 

     

     

     

     

    CUSIP No. 574795100   Page 4

     

    1

    NAME OF REPORTING PERSON

    Politan Capital Partners GP LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) x  (b) ¨

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    OO (See Item 3)

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

    ¨

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    Number of
    shares
    beneficially
    owned by
    each
    reporting
    person
    with
    7

    SOLE VOTING POWER

     

    0

    8

    SHARED VOTING POWER

     

    4,713,518

    9

    SOLE DISPOSITIVE POWER

     

    0

    10

    SHARED DISPOSITIVE POWER

     

    4,713,518

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,713,518

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    8.8%*

    14

    TYPE OF REPORTING PERSON

     

    IA

    * All percentage calculations set forth herein are based upon the aggregate of 53,470,864 shares of Common Stock outstanding as of August 12, 2024, as reported in the Issuer Revised Proxy Statement.  

     

     

     

     

    CUSIP No. 574795100   Page 5

     

    1

    NAME OF REPORTING PERSON

    Quentin Koffey

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) x  (b) ¨

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    OO (See Item 3)

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

    ¨

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    Number of
    shares
    beneficially
    owned by
    each
    reporting
    person
    with
    7

    SOLE VOTING POWER

     

    3,018*

    8

    SHARED VOTING POWER

     

    4,713,518

    9

    SOLE DISPOSITIVE POWER

     

    3,018*

    10

    SHARED DISPOSITIVE POWER

     

    4,713,518

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,716,536*

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    8.8%**

    14

    TYPE OF REPORTING PERSON

     

    IN

    * Includes Mr. Koffey’s 1,228 restricted share units granted to him on June 26, 2023 by virtue of his position as a director on the Board, which vested on June 26, 2024, and his 1,790 restricted share units granted to him on September 19, 2024 by virtue of his position as a director on the Board, which will vest on the earlier of the first anniversary of the grant date or the date of the Issuer’s 2025 annual meeting of stockholders.

    ** Mr. Koffey’s percentage calculations set forth herein are based upon the aggregate of 53,470,864 shares of Common Stock outstanding as of August 12, 2024, as reported in the Issuer Revised Proxy Statement.  

     

     

     

     

    CUSIP No. 574795100   Page 6

     

    This Amendment No. 15 to Schedule 13D (this “Amendment No. 15”) amends and supplements the Schedule 13D filed on August 16, 2022 (as amended and supplemented through the date of this Amendment No. 15, collectively, the “Schedule 13D”) by the Reporting Persons, relating to the common stock, par value $0.001 per share, of Masimo Corporation, a Delaware corporation (the “Issuer”). Capitalized terms not defined in this Amendment No. 15 shall have the meaning ascribed to them in the Schedule 13D.

     

    The information set forth in response to Item 4 below shall be deemed to be a response to all Items where such information is relevant.

     

    ITEM 4. PURPOSE OF TRANSACTION

     

    Item 4 of the Schedule 13D is hereby amended and supplemented with the following information:

     

    According to the final vote tabulation delivered to the Issuer by the independent inspector of election on September 24, 2024, in connection with the matters that were submitted to a vote at the 2024 Annual Meeting on September 19, 2024, the 2024 Nominees (William Jellison and Darlene Solomon) were elected to the Issuer’s Board at the 2024 Annual Meeting.

     

    ITEM 7. MATERIAL TO BE FILED AS AN EXHIBIT

     

    Exhibit 99.1 Joint Filing Agreement among Politan Capital Management LP, Politan Capital Management GP LLC, Politan Capital Partners GP LLC, and Quentin Koffey*
       
    Exhibit 99.2 Trading Data*
       
    Exhibit 99.3 Trading Data*
       
    Exhibit 99.4 Form of Verified Complaint, filed with the Delaware Court of Chancery on October 21, 2022*
       
    Exhibit 99.5 Form of Second Amended and Supplemented Complaint, filed as an Exhibit to the Motion for Leave to Amend with the Delaware Court of Chancery on March 10, 2023*
    Exhibit 99.6 Form of Engagement and Indemnification Agreement entered into by and between Politan Capital Management LP and Michelle Brennan*
    Exhibit 99.7 Trading Data*
    Exhibit 99.8 Press Release, dated June 26, 2023*
    Exhibit 99.9 Form of Engagement and Indemnification Agreement entered into by and between Politan Capital Management LP and each of William Jellison and Darlene Solomon*
    Exhibit 99.10 Demand Letter, dated May 8, 2024*
    Exhibit 99.11 Politan Letter, dated May 9, 2024*
    Exhibit 99.12 Politan Letter, dated July 3, 2024*
    Exhibit 99.13 Politan Letter, dated July 12, 2024*
    Exhibit 99.14 Politan Letter, dated July 15, 2024*
    Exhibit 99.15 Issuer’s Amended Complaint, filed August 26, 2024*
    Exhibit 99.16 Issuer’s Preliminary Injunction Motion, filed August 23, 2024*
    Exhibit 99.17 Politan’s Supplemental Proxy Materials, filed August 30, 2024*

     

    *Previously filed.

     

     

     

     

    CUSIP No. 574795100   Page 7

     

    SIGNATURES

     

    After reasonable inquiry and to the best of each of the undersigned’s knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: September 25, 2024

     

      POLITAN CAPITAL MANAGEMENT LP
             
      By: Politan Capital Management GP LLC
        its general partner
           
      By: /s/ Quentin Koffey  
        Name: Quentin Koffey
        Title: Managing Member
           
      POLITAN CAPITAL MANAGEMENT GP LLC
           
      By: /s/ Quentin Koffey  
        Name: Quentin Koffey
        Title: Managing Member
           
      POLITAN CAPITAL PARTNERS GP LLC
         
      By: /s/ Quentin Koffey  
        Name: Quentin Koffey
        Title: Managing Member
           
      QUENTIN KOFFEY
           
      By: /s/ Quentin Koffey  
        Name: Quentin Koffey
           

     

     

     

     

     

     

     

    CUSIP No. 574795100   Page 8

     

    INDEX TO EXHIBITS

     

    Exhibit

    Description

    Exhibit 99.1 Joint Filing Agreement among Politan Capital Management LP, Politan Capital Management GP LLC, Politan Capital Partners GP LLC, and Quentin Koffey*
       
    Exhibit 99.2 Trading Data*
       
    Exhibit 99.3 Trading Data*
       
    Exhibit 99.4 Form of Verified Complaint, filed with the Delaware Court of Chancery on October 21, 2022*
       
    Exhibit 99.5

    Form of Second Amended and Supplemented Complaint, filed as an Exhibit to the Motion for Leave to Amend with the Delaware Court of Chancery on March 10, 2023*

     

    Exhibit 99.6 Form of Engagement and Indemnification Agreement entered into by and between Politan Capital Management LP and Michelle Brennan*
    Exhibit 99.7 Trading Data*
    Exhibit 99.8 Press Release, dated June 26, 2023*
    Exhibit 99.9 Form of Engagement and Indemnification Agreement entered into by and between Politan Capital Management LP and each of William Jellison and Darlene Solomon*
    Exhibit 99.10 Demand Letter, dated May 8, 2024*
    Exhibit 99.11 Politan Letter, dated May 9, 2024*
    Exhibit 99.12 Politan Letter, dated July 3, 2024*
    Exhibit 99.13 Politan Letter, dated July 12, 2024*
    Exhibit 99.14 Politan Letter, dated July 15, 2024*
    Exhibit 99.15 Issuer’s Amended Complaint, filed August 26, 2024*
    Exhibit 99.16 Issuer’s Preliminary Injunction Motion, filed August 23, 2024*
    Exhibit 99.17 Politan’s Supplemental Proxy Materials, filed August 30, 2024*

     

    *Previously filed.

     

     

    Get the next $MASI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MASI

    DatePrice TargetRatingAnalyst
    12/27/2024$170.00 → $194.00Outperform
    Raymond James
    11/6/2024$170.00Mkt Perform → Outperform
    Raymond James
    6/3/2024$126.00 → $160.00Neutral → Overweight
    Piper Sandler
    4/15/2024$148.00 → $170.00Hold → Buy
    Stifel
    3/25/2024$117.00 → $160.00Equal Weight → Overweight
    Wells Fargo
    1/30/2024$107.00 → $121.00Buy → Hold
    Jefferies
    1/3/2024Buy → Hold
    Needham
    11/8/2023Outperform → Mkt Perform
    Raymond James
    More analyst ratings

    $MASI
    SEC Filings

    See more
    • Masimo Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - MASIMO CORP (0000937556) (Filer)

      6/12/25 4:17:11 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SD filed by Masimo Corporation

      SD - MASIMO CORP (0000937556) (Filer)

      5/27/25 5:27:13 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Masimo Corporation filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - MASIMO CORP (0000937556) (Filer)

      5/27/25 9:00:17 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MASI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Muhsin Bilal exercised 10,000 shares at a strike of $34.51 and sold $1,632,781 worth of shares (10,000 units at $163.28) (SEC Form 4)

      4 - MASIMO CORP (0000937556) (Issuer)

      5/14/25 5:32:56 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Solomon Darlene J. S. converted options into 1,790 shares (SEC Form 4)

      4 - MASIMO CORP (0000937556) (Issuer)

      5/2/25 8:55:57 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Scannell Timothy J converted options into 1,383 shares (SEC Form 4)

      4 - MASIMO CORP (0000937556) (Issuer)

      5/2/25 8:54:23 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MASI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Raymond James reiterated coverage on Masimo with a new price target

      Raymond James reiterated coverage of Masimo with a rating of Outperform and set a new price target of $194.00 from $170.00 previously

      12/27/24 7:29:29 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Masimo upgraded by Raymond James with a new price target

      Raymond James upgraded Masimo from Mkt Perform to Outperform and set a new price target of $170.00

      11/6/24 7:17:22 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Masimo upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Masimo from Neutral to Overweight and set a new price target of $160.00 from $126.00 previously

      6/3/24 7:31:43 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MASI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • New Study Finds Masimo SedLine® Brain Function Monitoring Offers Significant Advantages During Pediatric Anesthesia

      EEG-Guided Anesthesia Using Masimo Technology Significantly Reduced Pediatric Anesthesia Emergence Delirium, Time to Emergence and Discharge, and Cost of Care by Minimizing Sevoflurane Exposure Masimo (NASDAQ:MASI) today announced the findings of a randomized clinical trial published in JAMA Pediatrics in which Dr. Yasuko Nagasaka and colleagues at Tokyo Women's Medical University demonstrated the ability of electroencephalogram (EEG)-guided anesthesia, using Masimo SedLine® Brain Function Monitoring, to improve anesthesia administration in children undergoing surgery.1 The researchers found that the use of SedLine led to a significant reduction in the amount of a commonly used inhalation

      6/10/25 8:00:00 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Masimo to Present in the Jefferies Global Healthcare Conference

      Masimo (NASDAQ:MASI) today announced that its management will participate in the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 1:25 p.m. Eastern time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (NASDAQ:MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bower

      5/27/25 9:00:00 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Masimo to Present in the BofA Securities 2025 Health Care Conference

      Masimo (NASDAQ:MASI) today announced that its management will participate in the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025 at 4:20 p.m. Pacific time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (NASDAQ:MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bo

      5/7/25 9:00:00 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MASI
    Leadership Updates

    Live Leadership Updates

    See more
    • Dexcom Appoints Jon Coleman as Chief Commercial Officer

      DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom's global commercial organization, including global sales, marketing and customer experience. Mr. Coleman joins Dexcom with more than 30 years of global commercial leadership experience across multiple healthcare segments and channels. Mr. Coleman served as an executive officer of Masimo Corporation (NASDAQ:MASI), where he held roles of increasing responsibility across his fifteen-year tenure. This included serving as president of Masimo's commercial teams where he oversaw the consolid

      3/25/25 4:05:00 PM ET
      $DXCM
      $MASI
      $PFE
      Medical/Dental Instruments
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Biotechnology: Pharmaceutical Preparations
    • Masimo Announces Leadership Transition

      Katie Szyman Appointed Chief Executive Officer and to Board of Directors Interim CEO Michelle Brennan Named Chairman of Masimo's Board Today the Board of Directors (the "Board") of Masimo (NASDAQ:MASI), a leading global medical innovator, announced that Katie Szyman has been appointed the next Chief Executive Officer ("CEO") of the Company. Interim CEO Michelle Brennan has been appointed Chairman of Masimo's Board and Lead Independent Director Quentin Koffey has been appointed Vice Chairman. All of these changes are effective as of February 12, 2025. Ms. Szyman is currently worldwide president of Advanced Patient Monitoring at BD (Becton, Dickinson and Company). Previously, Ms. Szyman

      1/21/25 4:00:00 PM ET
      $MASI
      $NARI
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medical/Dental Instruments
    • Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors

      Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board Masimo Corporation (NASDAQ:MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the "Board"), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, "We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals who will bring critical perspectives to the Board and possess expertise that closely aligns

      10/18/24 9:00:00 AM ET
      $ENV
      $LH
      $MASI
      $MSCI
      Business Services
      Consumer Discretionary
      Medical Specialities
      Health Care

    $MASI
    Financials

    Live finance-specific insights

    See more
    • Masimo Reports First Quarter 2025 Results

      Masimo Corporation (NASDAQ:MASI) today announced its financial results for the first quarter ended March 29, 2025. First Quarter 2025 Results From Continuing Operations(1): GAAP revenue of $372 million, representing 10% on a reported basis; Non-GAAP revenue of $371 million, representing 10% on a constant currency basis(3); GAAP net income per diluted of $0.86; and Non-GAAP net income per diluted share(3) of $1.36, which grew 56% versus prior year period. First Quarter 2025 Results From Discontinued Operations(2): GAAP loss from discontinued operations, net of tax was ($218) million, which included an impairment of intangibles of $295 million for the non-healthcare consumer busi

      5/6/25 4:10:00 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Masimo to Report First Quarter 2025 Financial Results after Market Close on Tuesday, May 6

      Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) Masimo (NASDAQ:MASI) will release first quarter 2025 financial results for the period ended March 29, 2025, after the market closes on Tuesday, May 6, 2025. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Katie Szyman, Chief Executive Officer, and Micah Young, Chief Financial Officer. To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with details including the dial-in number and a registrant ID number. Reminders about the call will also be sent to registered participant

      4/24/25 9:00:00 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Masimo Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Updated Full-Year 2025 Guidance

      Masimo (NASDAQ:MASI) today announced its financial results for the fourth quarter and full-year ended December 28, 2024 and provided updated estimates for its full-year 2025 guidance. Fourth Quarter 2024 Financial Results: Consolidated revenue was $601 million, representing 9% growth on a reported and constant currency basis(1); Healthcare revenue was $368 million, representing 8% growth on a reported basis and 9% growth on a constant currency basis(1); Non-healthcare revenue was $232 million, representing 11% growth on a reported and constant currency basis(1); GAAP net loss per basic share was ($6.52), which included an impairment of goodwill and intangibles for Sound United

      2/25/25 4:05:00 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $MASI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Masimo Corporation

      SC 13D/A - MASIMO CORP (0000937556) (Subject)

      9/25/24 4:01:23 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Masimo Corporation

      SC 13D/A - MASIMO CORP (0000937556) (Subject)

      8/30/24 4:56:53 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Masimo Corporation

      SC 13D/A - MASIMO CORP (0000937556) (Subject)

      7/17/24 5:29:36 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care